دورية أكاديمية
أعرض في EDS

HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer.

التفاصيل البيبلوغرافية
العنوان: HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer.
المؤلفون: Besse A; Laboratory of Experimental Oncology, Department of Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, 9000, Switzerland.; Department of Biology, Faculty of Medicine, Masaryk University, Brno, 62500, Czech Republic., Sedlarikova L; Babak Myeloma Group, Department of Pathological Physiology, Masaryk University, Brno, 62500, Czech Republic.; Department of Biology, Faculty of Medicine, Masaryk University, Brno, 62500, Czech Republic., Buechler L; Laboratory of Experimental Oncology, Department of Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, 9000, Switzerland., Kraus M; Laboratory of Experimental Oncology, Department of Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, 9000, Switzerland., Yang CH; Department of Oncological Sciences, University of Utah, Salt Lake City, UT, USA.; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Strakova N; Department of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, 612 00, Czech Republic.; Veterinary Research Institute, Brno, 62500, Czech Republic., Soucek K; Department of Cytokinetics, Institute of Biophysics of the Czech Academy of Sciences, Brno, 612 00, Czech Republic.; International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic., Navratil J; Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, 62500, Czech Republic.; Faculty of Medicine, Masaryk University, Brno, 62500, Czech Republic., Svoboda M; Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, 62500, Czech Republic.; Faculty of Medicine, Masaryk University, Brno, 62500, Czech Republic., Welm AL; Department of Oncological Sciences, University of Utah, Salt Lake City, UT, USA.; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA., Joerger M; Department of Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, 9000, Switzerland., Driessen C; Laboratory of Experimental Oncology, Department of Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, 9000, Switzerland.; Department of Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, 9000, Switzerland., Besse L; Laboratory of Experimental Oncology, Department of Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, 9000, Switzerland. Lenka.besse@kssg.ch.; Department of Biology, Faculty of Medicine, Masaryk University, Brno, 62500, Czech Republic. Lenka.besse@kssg.ch.
المصدر: British journal of cancer [Br J Cancer] 2024 Sep; Vol. 131 (5), pp. 918-930. Date of Electronic Publication: 2024 Jul 05.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: 2002- : London : Nature Publishing Group on behalf of Cancer Research UK
Original Publication: London, Lewis.
مواضيع طبية MeSH: Triple Negative Breast Neoplasms*/drug therapy , Triple Negative Breast Neoplasms*/pathology , Oligopeptides*/pharmacology , HIV Protease Inhibitors*/pharmacology , Nelfinavir*/pharmacology , Lopinavir*/pharmacology , Drug Synergism* , Bortezomib*/pharmacology , ATP Binding Cassette Transporter, Subfamily G, Member 2*/metabolism , ATP Binding Cassette Transporter, Subfamily G, Member 2*/antagonists & inhibitors , Unfolded Protein Response*/drug effects, Humans ; Cell Line, Tumor ; Female ; Proteasome Inhibitors/pharmacology ; Neoplasm Proteins/antagonists & inhibitors ; Neoplasm Proteins/metabolism ; X-Box Binding Protein 1/metabolism ; X-Box Binding Protein 1/genetics ; ATP Binding Cassette Transporter, Subfamily B/metabolism ; Endoplasmic Reticulum Stress/drug effects ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Apoptosis/drug effects
مستخلص: Background: Resistance to chemotherapy is a major problem in the treatment of patients with triple-negative breast cancer (TNBC). Preclinical data suggest that TNBC is dependent on proteasomes; however, clinical observations indicate that the efficacy of proteasome inhibitors in TNBC may be limited, suggesting the need for combination therapies.
Methods: We compared bortezomib and carfilzomib and their combinations with nelfinavir and lopinavir in TNBC cell lines and primary cells with regard to their cytotoxic activity, functional proteasome inhibition, and induction of the unfolded protein response (UPR). Furthermore, we evaluated the involvement of sXBP1, ABCB1, and ABCG2 in the cytotoxic activity of drug combinations.
Results: Carfilzomib, via proteasome β5 + β2 inhibition, is more cytotoxic in TNBC than bortezomib, which inhibits β5 + β1 proteasome subunits. The cytotoxicity of carfilzomib was significantly potentiated by nelfinavir or lopinavir. Carfilzomib with lopinavir induced endoplasmic reticulum stress and pro-apoptotic UPR through the accumulation of excess proteasomal substrate protein in TNBC in vitro. Moreover, lopinavir increased the intracellular availability of carfilzomib by inhibiting carfilzomib export from cells that express high levels and activity of ABCB1, but not ABCG2.
Conclusion: Proteasome inhibition by carfilzomib combined with nelfinavir/lopinavir represents a potential treatment option for TNBC, warranting further investigation.
(© 2024. The Author(s).)
References: Free Radic Biol Med. 2013 Dec;65:778-788. (PMID: 23973637)
Cell Death Discov. 2024 Jan 29;10(1):57. (PMID: 38286854)
Blood. 2009 Oct 15;114(16):3439-47. (PMID: 19671918)
Cancer Res. 2021 Sep 1;81(17):4581-4593. (PMID: 34158378)
Elife. 2017 Dec 18;6:. (PMID: 29251598)
Biosci Rep. 2003 Aug;23(4):199-212. (PMID: 14763437)
Genomics Proteomics Bioinformatics. 2022 Jun;20(3):587-596. (PMID: 35085776)
STAR Protoc. 2023 Sep 15;4(3):102402. (PMID: 37402170)
Clin Cancer Res. 2007 Sep 1;13(17):5183-94. (PMID: 17785575)
Haematologica. 2016 Mar;101(3):346-55. (PMID: 26659919)
J Natl Cancer Inst. 2012 Oct 17;104(20):1576-90. (PMID: 23042933)
Mol Biol Cell. 2010 Jun 15;21(12):1909-21. (PMID: 20410136)
Nat Rev Mol Cell Biol. 2005 Jan;6(1):79-87. (PMID: 15688069)
J Control Release. 2022 Dec;352:637-651. (PMID: 36349616)
Cell. 2012 Aug 3;150(3):549-62. (PMID: 22863008)
Cancer Cell. 2013 Aug 12;24(2):182-96. (PMID: 23948298)
Haematologica. 2015 Oct;100(10):1350-60. (PMID: 26069288)
JCO Precis Oncol. 2017;2017:. (PMID: 29888341)
Cell Rep. 2017 Mar 28;18(13):3143-3154. (PMID: 28355566)
Br J Cancer. 2018 Mar 20;118(6):813-819. (PMID: 29462126)
Cell Death Dis. 2012 Jul 19;3:e353. (PMID: 22825471)
Leuk Res. 2014 Mar;38(3):383-92. (PMID: 24418752)
J Biol Chem. 2006 Mar 31;281(13):8582-90. (PMID: 16455650)
BJU Int. 2018 Apr;121(4):600-609. (PMID: 29161753)
Cell Chem Biol. 2016 May 19;23(5):567-578. (PMID: 27185638)
Cell Chem Biol. 2019 Mar 21;26(3):340-351.e3. (PMID: 30612952)
Haematologica. 2012 Jan;97(1):64-72. (PMID: 21993678)
Cell. 2001 Dec 28;107(7):881-91. (PMID: 11779464)
Leuk Lymphoma. 2022 Jul;63(7):1738-1741. (PMID: 35147474)
Cancers (Basel). 2020 Apr 25;12(5):. (PMID: 32344880)
Sci Rep. 2023 Mar 17;13(1):4411. (PMID: 36932175)
Leukemia. 2018 Feb;32(2):391-401. (PMID: 28676669)
J Cell Biochem. 2017 May;118(5):1239-1248. (PMID: 27813130)
Comput Struct Biotechnol J. 2015 Sep 25;13:504-13. (PMID: 26949479)
Front Oncol. 2020 Jan 22;9:1530. (PMID: 32039016)
Nat Cancer. 2022 Feb;3(2):232-250. (PMID: 35221336)
Haematologica. 2023 Jun 01;108(6):1628-1639. (PMID: 36727403)
Lab Invest. 2013 Nov;93(11):1254-8. (PMID: 24042438)
J Biol Chem. 1997 Oct 3;272(40):25200-9. (PMID: 9312134)
Blood Cancer J. 2013 Mar 01;3:e103. (PMID: 23454896)
Cancer Res. 2020 Jun 1;80(11):2368-2379. (PMID: 32265225)
Leukemia. 2009 Jun;23(6):1098-105. (PMID: 19225532)
Mol Cancer Res. 2018 May;16(5):745-753. (PMID: 29440447)
Nature. 2014 Apr 3;508(7494):103-107. (PMID: 24670641)
Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):10976-83. (PMID: 10500111)
Angew Chem Int Ed Engl. 2016 Mar 18;55(13):4199-203. (PMID: 26511210)
Cell Chem Biol. 2017 Feb 16;24(2):218-230. (PMID: 28132893)
Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7156-61. (PMID: 9207060)
Cell Rep. 2015 May 12;11(6):990. (PMID: 28843283)
Life Sci Alliance. 2020 May 18;3(7):. (PMID: 32423906)
معلومات مُعتمدة: U54 CA224076 United States CA NCI NIH HHS; NU-21-08-00023 Agentura Pro Zdravotnický Výzkum České Republiky (Czech Health Research Council); KFS-4990-02-2020 Krebsliga Schweiz (Ligue Suisse Contre le Cancer); U54CA224076 U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
المشرفين على المادة: 72X6E3J5AR (carfilzomib)
0 (Oligopeptides)
0 (HIV Protease Inhibitors)
HO3OGH5D7I (Nelfinavir)
2494G1JF75 (Lopinavir)
69G8BD63PP (Bortezomib)
0 (ATP Binding Cassette Transporter, Subfamily G, Member 2)
0 (Proteasome Inhibitors)
0 (ABCB1 protein, human)
0 (ABCG2 protein, human)
0 (Neoplasm Proteins)
0 (X-Box Binding Protein 1)
0 (ATP Binding Cassette Transporter, Subfamily B)
0 (XBP1 protein, human)
تواريخ الأحداث: Date Created: 20240705 Date Completed: 20240902 Latest Revision: 20240905
رمز التحديث: 20240905
مُعرف محوري في PubMed: PMC11368961
DOI: 10.1038/s41416-024-02774-9
PMID: 38969867
قاعدة البيانات: MEDLINE
الوصف
تدمد:1532-1827
DOI:10.1038/s41416-024-02774-9